Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to developing targeted genetic medicines and oncolytic virotherapies to combat cancer. The company's core mission revolves around pioneering therapies that arm the immune system to effectively fight cancer by delivering genetic medicines to tumor sites. Headquartered in San Diego, California, Calidi Biotherapeutics was founded in 2014.

Calidi Biotherapeutics' pipeline features several proprietary platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced efficacy and patient safety. Key platforms include RedTail, a systemic delivery platform utilizing an engineered enveloped oncolytic virus for metastatic cancers; NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus for high-grade gliomas; and SuperNova, using allogeneic adipose-derived mesenchymal stem cells with an oncolytic vaccinia virus for solid tumors. Lead product candidates include CLD-401 (from the RedTail platform, an IL-15 superagonist for solid tumors), CLD-101 (NeuroNova for high-grade gliomas), and CLD-201 (SuperNova for advanced metastatic solid tumors like TNBC, SCCHN, and Sarcoma).

Recent notable developments for Calidi Biotherapeutics include a public offering in March 2026 and a partnership with Avance Clinical to facilitate Australian regulatory approval and accelerate clinical trials for CLD-401. The company has also presented new data on its RedTail platform and CLD-401 at the AACR Annual Meeting in April 2026 and partnered with TransferAI to leverage AI in the IND submission process for CLD-401. Dr. Eric Poma serves as the Chief Executive Officer and Director, having been appointed in May 2025, succeeding Allan Camaisa, who is now CEO Emeritus and Director. Calidi Biotherapeutics became a publicly traded company in September 2023 through a merger with a special purpose acquisition company (SPAC).

Latest updates

Calidi Biotherapeutics Leverages AI to Expedite Regulatory Pathway for Lead Candidate

Event summary

  • Calidi Biotherapeutics has partnered with TransferAI to utilize TransferAI’s agentic AI platform, Sofie, for its IND submission for CLD-401.
  • CLD-401 is Calidi’s lead candidate, a virotherapy platform targeting tumors and expressing IL-15 superagonist.
  • The IND submission for CLD-401 is currently expected by year-end 2026.
  • TransferAI’s Sofie platform aims to streamline regulatory workflows by orchestrating research, drafting, and review activities.

The big picture

Calidi’s partnership with TransferAI reflects a growing trend in the biopharmaceutical industry to leverage AI and automation to accelerate drug development and navigate increasingly complex regulatory pathways. The use of agentic AI, which actively orchestrates workflows, represents a more advanced application than simple data analysis and could significantly reduce the time and cost associated with IND submissions, a critical bottleneck in bringing new therapies to market. This move also highlights the increasing commoditization of regulatory expertise, with specialized AI platforms now offering a viable alternative to traditional consultants.

What we're watching

Execution Risk
The success of this partnership hinges on TransferAI’s Sofie platform’s ability to integrate effectively with Calidi’s existing regulatory processes and deliver on its promised efficiencies, which could impact the year-end IND filing timeline.
Regulatory Headwinds
While AI can streamline processes, the FDA’s acceptance and validation of AI-driven regulatory submissions remains an open question, and any pushback could delay Calidi’s IND timeline.
Competitive Landscape
The adoption of agentic AI in biopharma regulatory workflows is nascent; the pace at which competitors adopt similar solutions will influence Calidi’s ability to maintain a competitive advantage in clinical development.
CID: 3057